ABT Cash-Secured Put Strategy
ABT (Abbott Laboratories), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
ABT (Abbott Laboratories) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $146.00B, a trailing P/E of 23.33, a beta of 0.65 versus the broader market, a 52-week range of 81.97-139.06, average daily share volume of 13.0M, a public-listing history dating back to 1980, approximately 114K full-time employees. These structural characteristics shape how ABT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.65 indicates ABT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. ABT pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a cash-secured put on ABT?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current ABT snapshot
As of May 15, 2026, spot at $84.50, ATM IV 28.79%, IV rank 65.68%, expected move 8.25%. The cash-secured put on ABT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this cash-secured put structure on ABT specifically: ABT IV at 28.79% is mid-range versus its 1-year history, so the credit collected on a ABT cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 8.25% (roughly $6.97 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABT should anchor to the underlying notional of $84.50 per share and to the trader's directional view on ABT stock.
ABT cash-secured put setup
The ABT cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABT near $84.50, the first option leg uses a $80.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABT chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $80.00 | $0.85 |
ABT cash-secured put risk and reward
- Net Premium / Debit
- +$85.00
- Max Profit (per contract)
- $85.00
- Max Loss (per contract)
- -$7,914.00
- Breakeven(s)
- $79.15
- Risk / Reward Ratio
- 0.011
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
ABT cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on ABT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$7,914.00 |
| $18.69 | -77.9% | -$6,045.77 |
| $37.37 | -55.8% | -$4,177.54 |
| $56.06 | -33.7% | -$2,309.31 |
| $74.74 | -11.6% | -$441.08 |
| $93.42 | +10.6% | +$85.00 |
| $112.10 | +32.7% | +$85.00 |
| $130.79 | +54.8% | +$85.00 |
| $149.47 | +76.9% | +$85.00 |
| $168.15 | +99.0% | +$85.00 |
When traders use cash-secured put on ABT
Cash-secured puts on ABT earn premium while a trader waits to acquire ABT stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ABT.
ABT thesis for this cash-secured put
The market-implied 1-standard-deviation range for ABT extends from approximately $77.53 on the downside to $91.47 on the upside. A ABT cash-secured put lets a trader earn premium while waiting to acquire ABT at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current ABT IV rank near 65.68% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on ABT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABT-specific events.
ABT cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABT alongside the broader basket even when ABT-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on ABT carry tail risk when realized volatility exceeds the implied move; review historical ABT earnings reactions and macro stress periods before sizing. Always rebuild the position from current ABT chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on ABT?
- A cash-secured put on ABT is the cash-secured put strategy applied to ABT (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With ABT stock trading near $84.50, the strikes shown on this page are snapped to the nearest listed ABT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABT cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the ABT cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 28.79%), the computed maximum profit is $85.00 per contract and the computed maximum loss is -$7,914.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABT cash-secured put?
- The breakeven for the ABT cash-secured put priced on this page is roughly $79.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABT market-implied 1-standard-deviation expected move is approximately 8.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on ABT?
- Cash-secured puts on ABT earn premium while a trader waits to acquire ABT stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ABT.
- How does current ABT implied volatility affect this cash-secured put?
- ABT ATM IV is at 28.79% with IV rank near 65.68%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.